Currently also CEO at Cereno Scientific AB and Chairman of the Board at Stayble Therapeutics AB and AcuCort AB. A seasoned professional with international experience in various sectors, including Pharmaceutical, Biotechnology, Finance, Renewable Energy, and Management Consulting. Assignments include senior global positions at AstraZeneca and Monsanto/GD Searle, CEO and Board member at Pharma Start Up Cortendo, Sector Head Life Science, Med Tech, Pharma & Private Equity at PwC, VP Bus Dev and Board Member at Eurowind.
Leading co-founder of ExpreS2ion Biotechnologies ApS, a wholly owned subsidiary of ExpreS2ion Biotech Holding AB, which was listed at Nasdaq First North in 2016. She was the main driver in the company's spin-out from Affitech A/S in 2010 and led the company as CEO. In addition, as a board member of ExpreS2ion, she was an integral part of the successful IPO. Charlotte is presently the owner and CEO of Caballus Biotech, delivering consulting services to the life science industry and evaluations of European grant applications. Charlotte has over 25 years of experience working in several scientific and managerial positions in the pharmaceutical and biotechnology industries at Pharmacia & Upjohn AB, Pharmexa A/S, and Affitech A/S. Besides management, she has an extensive track record in protein expression in animal cells, upstream process development, and process transfer to cGMP manufacturing.
Director NMR services and co-founder of SARomics Biostructures AB. Professor, Professor of Physical Chemistry at Lund University since 2005. He is an expert in biomolecular NMR spectroscopy. His current research includes fundamental studies of the driving forces underlying ligand binding.
Dr. Björn Walse, co-founder, and Chief Executive Officer of SARomics Biostructures AB has over 25 years of drug discovery and research management experience from the biotech industry. Before establishing SARomics Biostructures, Dr. Walse served as head of structural chemistry at Active Biotech AB, where he was responsible for building and running the structural chemistry platform. At Active Biotech, he also participated in the molecular design of biopharmaceutical therapeutics for an oncology indication. Before this, Dr. Walse performed postdoctoral research at UC Berkeley. Dr. Walse received his Doctorate in physical chemistry from Lund University and his M.Sc. in Chemical Engineering from Lund Institute of Technology.